Platelet lung cancer

Choi, J.H., Kim, C., Lim, H. Y. et al. 2001. Vascular endothelial growth factor in the serum of patients with nonsmall cell lung cancer Correlation with platelet and leukocyte counts. Lung Cancer 33 171-179. 

Giatromanolaki A, Koukourakis M, Comley M, Kaklamanis L, Turley H, O Byrne K, et al. Platelet-derived endothelial cell growth factor (thymidine phosphorylase) expression in lung cancer. J Pathol 1997 181 196-199. 

Recent studies have shown that platelets ate one of the cytotoxic effector cells against neoplasia (for review Okada et al 1996). It has been shown that the cytotoxic effects of activated platelets against lung cancer cells in culture may depend on the activity of platelet NOS (Okada et al 1996). 

Abrams, T.J., Lee, L.B., Murray, L.J., Pryer, N.K., Cherrington, J.M. SU11248 inhibits KIT and platelet-derived growth factor receptor beta in precUnical models of human small cell lung cancer. Molecular Cancer Therapeutics 2(5), 471- 78 (2003)... 

For a review of bothP450 5A1 inhibitors and thromboxane receptors, which have been used together, see [1691]. Quantitative stracture-ac-tivity relationships of both have been reviewed [1692]. Among the uses for P450 5A1 inhibitors are platelet function [1693], atherosclerosis [1694], inflammatory bowel disease [1695], lung cancer [1696], and production of hepatitis C virus (in a humanized mouse model) [1697]. 

Struyf, S., M.D. Burdick, E. Peeters, K. Van den Broeck, C. Dillen, P. Proost, J. Van Damme, and R.M. Strieter. Platelet factor-4 variant chemokine CXCL4L1 inhibits melanoma and lung carcinoma growth and metastasis by preventing angiogenesis. Cancer Res 67 5940-8, 2007. 

---